(Total Views: 451)
Posted On: 05/10/2022 6:01:48 PM
Post# of 148878
Agree, Figgs, we need stellar NASH results.
However, from what I've seen in various small stocks over the last 15 years, great results don't necessarily correlate with a rise in SP. In fact, I would say just the reverse is true, at least with small (non NASDAQ) companies.
Maybe I'm slow to catch on, or maybe I just don't want to believe the retail buying market can be so corrupt. But the more 'good results/SP slaughtered' examples I see (like NWBO), the more times I see CYDY fail to get traction in the PI or UK/Canada or (with trials) in Brazil, the more I'm convinced of market maker/short seller corruption, the more I'm convinced BP has a free hand to quash all potential competition through nefarious means (bribes, kickbacks, etc).
No way a ton of NWBO retail shareholders sold on today's news. And no way we drop from $10 to $4 on 30 June 2020 without massive manipulation.
From a life-saving perspective, it's all about study results. From a shareholder perspective, it's all about political and monetary clout, so we either partner up or get bought out. Sad to say, but I 100% believe a small biotech could announce a cure for cancer . . .and suffer a 95% SP decline.
That said, we do have a miracle drug. So partner(s) or buy-out, I'm all in.
However, from what I've seen in various small stocks over the last 15 years, great results don't necessarily correlate with a rise in SP. In fact, I would say just the reverse is true, at least with small (non NASDAQ) companies.
Maybe I'm slow to catch on, or maybe I just don't want to believe the retail buying market can be so corrupt. But the more 'good results/SP slaughtered' examples I see (like NWBO), the more times I see CYDY fail to get traction in the PI or UK/Canada or (with trials) in Brazil, the more I'm convinced of market maker/short seller corruption, the more I'm convinced BP has a free hand to quash all potential competition through nefarious means (bribes, kickbacks, etc).
No way a ton of NWBO retail shareholders sold on today's news. And no way we drop from $10 to $4 on 30 June 2020 without massive manipulation.
From a life-saving perspective, it's all about study results. From a shareholder perspective, it's all about political and monetary clout, so we either partner up or get bought out. Sad to say, but I 100% believe a small biotech could announce a cure for cancer . . .and suffer a 95% SP decline.
That said, we do have a miracle drug. So partner(s) or buy-out, I'm all in.
(4)
(0)Scroll down for more posts ▼
